drugset / Trial / NCT00133198

Efficacy and Safety of Pramipexole Compared to Placebo in the Treatment of Restless Legs Syndrome (RLS)

NCT00133198

Phase 3 Completed 345 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

A 12 week clinical trial was conducted in the United States in order to compare pramipexole (Mirapex®) versus placebo for the ability to reduce the symptoms of restless legs syndrome in adult subjects.

Timeline

Start
2004-04
Primary completion
2005-02
Completion
2005-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Pramipexole Unknown 0.25 mg Oral
Subject Pramipexole Unknown 0.5 mg Oral
Subject Pramipexole Unknown 0.75 mg Oral